Neurocrine Biosciences, Inc. (NASDAQ:NBIX) received a $60.00 price target from Oppenheimer Holdings, Inc. in a note issued to investors on Tuesday. The brokerage presently has a “buy” rating on the stock. Oppenheimer Holdings, Inc.’s target price indicates a potential upside of 39.05% from the stock’s current price.

NBIX has been the subject of a number of other research reports. Piper Jaffray Companies restated an “overweight” rating and issued a $96.00 target price on shares of Neurocrine Biosciences in a research report on Wednesday, December 7th. Cowen and Company set a $65.00 target price on Neurocrine Biosciences and gave the stock a “buy” rating in a research report on Wednesday, January 18th. BMO Capital Markets reiterated an “outperform” rating and issued a $72.00 price objective (up previously from $66.00) on shares of Neurocrine Biosciences in a research report on Thursday, October 27th. Robert W. Baird reiterated a “buy” rating and issued a $66.00 price objective on shares of Neurocrine Biosciences in a research report on Sunday, January 8th. Finally, ICAP reiterated an “outperform” rating and issued a $55.00 price objective on shares of Neurocrine Biosciences in a research report on Friday, February 10th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and fourteen have issued a buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus target price of $67.23.

Analyst Recommendations for Neurocrine Biosciences (NASDAQ:NBIX)

Shares of Neurocrine Biosciences (NASDAQ:NBIX) traded up 1.65% during mid-day trading on Tuesday, hitting $43.15. Neurocrine Biosciences has a 52 week low of $32.18 and a 52 week high of $55.15. The firm’s market cap is $3.75 billion. The company has a 50-day moving average price of $41.73 and a 200 day moving average price of $46.17.

Neurocrine Biosciences (NASDAQ:NBIX) last released its earnings results on Tuesday, February 14th. The company reported ($0.51) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.56) by $0.05. During the same period in the prior year, the company posted ($0.34) earnings per share. Equities analysts forecast that Neurocrine Biosciences will post ($2.13) earnings per share for the current fiscal year.

“Neurocrine Biosciences, Inc. (NBIX) Given a $60.00 Price Target by Oppenheimer Holdings, Inc. Analysts” was first published by Watch List News and is owned by of Watch List News. If you are reading this article on another site, it was illegally copied and reposted in violation of U.S. and international copyright & trademark laws. The legal version of this article can be read at http://www.watchlistnews.com/neurocrine-biosciences-inc-nbix-given-a-60-00-price-target-by-oppenheimer-holdings-inc-analysts/1121362.html.

In related news, insider Haig P. Bozigian sold 1,625 shares of the company’s stock in a transaction that occurred on Tuesday, January 17th. The stock was sold at an average price of $40.63, for a total transaction of $66,023.75. Following the completion of the transaction, the insider now owns 114,704 shares in the company, valued at $4,660,423.52. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, CEO Kevin Charles Gorman sold 3,010 shares of the company’s stock in a transaction that occurred on Monday, February 6th. The shares were sold at an average price of $43.18, for a total value of $129,971.80. Following the transaction, the chief executive officer now owns 250,542 shares of the company’s stock, valued at approximately $10,818,403.56. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 32,816 shares of company stock valued at $1,387,036. 4.80% of the stock is owned by corporate insiders.

Institutional investors have recently made changes to their positions in the stock. Perceptive Advisors LLC acquired a new position in shares of Neurocrine Biosciences during the fourth quarter worth approximately $128,349,000. Bank of New York Mellon Corp increased its position in shares of Neurocrine Biosciences by 238.4% in the third quarter. Bank of New York Mellon Corp now owns 1,406,038 shares of the company’s stock worth $71,202,000 after buying an additional 990,488 shares in the last quarter. Baker BROS. Advisors LP acquired a new position in shares of Neurocrine Biosciences during the third quarter worth approximately $45,344,000. Franklin Resources Inc. increased its position in shares of Neurocrine Biosciences by 19.8% in the fourth quarter. Franklin Resources Inc. now owns 2,409,715 shares of the company’s stock worth $93,256,000 after buying an additional 397,429 shares in the last quarter. Finally, Great Point Partners LLC acquired a new position in shares of Neurocrine Biosciences during the third quarter worth approximately $19,956,000. Institutional investors own 97.60% of the company’s stock.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc is engaged in the development of pharmaceutical products focused on neurological and endocrine-based diseases and disorders. The Company’s two lead late-stage clinical programs are Elagolix, a gonadotropin-releasing hormone (GnRH) antagonist for women’s health that is partnered with AbbVie Inc (AbbVie), and NBI-98854 (valbenazine), a vesicular monoamine transporter 2 (VMAT2) inhibitor for the treatment of movement disorders.

5 Day Chart for NASDAQ:NBIX

Receive News & Ratings for Neurocrine Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.